Evidence map›Paper›PMID 42197164›Full record

ArticleMolecules (Basel, Switzerland)2026

Multi-Omics Analysis and In Vitro Experimental Validation Identify Candidate Mechanisms of Baicalein Against Chronic Obstructive Pulmonary Disease.

Yinan Liu, Xuhua Yuan, Wei Shi, Zhidong Qiu, Xuelian Dong

Abstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Yinan LiuSchool of Pharmacy, Changchun University of Chinese Medicine, No. 1035 Boshuo Road, Jingyue National High-Tech Industrial Development Zone, Changchun 130117, China.
Xuhua YuanSchool of Pharmacy, Changchun University of Chinese Medicine, No. 1035 Boshuo Road, Jingyue National High-Tech Industrial Development Zone, Changchun 130117, China.
Wei ShiSchool of Pharmacy, Changchun University of Chinese Medicine, No. 1035 Boshuo Road, Jingyue National High-Tech Industrial Development Zone, Changchun 130117, China.
Zhidong QiuSchool of Pharmacy, Changchun University of Chinese Medicine, No. 1035 Boshuo Road, Jingyue National High-Tech Industrial Development Zone, Changchun 130117, China.
Xuelian DongSchool of Pharmacy, Changchun University of Chinese Medicine, No. 1035 Boshuo Road, Jingyue National High-Tech Industrial Development Zone, Changchun 130117, China.

Funding

Jilin Province Science and Technology Department 20220204002YY
6 · The paper itself

Abstract

Chronic obstructive pulmonary disease (COPD) is characterized by persistent airflow limitation, chronic airway inflammation, and immune dysregulation, and currently available therapies remain insufficient to effectively halt disease progression. In this study, we used an integrative, hypothesis-generating strategy to investigate the potential mechanisms of baicalein against COPD by combining multi-dataset transcriptomic analysis, single-cell transcriptomics, machine learning-based feature selection, Mendelian randomization (MR), molecular simulation, virtual knockout analysis, and in vitro validation. Putative targets of baicalein were predicted using CTD, SEA, and SwissTargetPrediction, and were intersected with COPD-related genes collected from GeneCards and OMIM. Four GEO datasets (GSE20257, GSE42057, GSE76925, and GSE130928) were integrated after batch-effect correction, yielding a combined cohort of 260 control samples and 250 COPD samples. Candidate genes were prioritized by intersecting the results of LASSO regression, random forest, and support vector machine. Immune-cell infiltration was estimated using CIBERSORT, and single-cell transcriptomic data were used to define the cellular localization of prioritized genes. Formal protein-level MR analysis was conducted for CD163 using deCODE plasma protein pQTL/GWAS summary statistics as the exposure dataset and the IEU OpenGWAS COPD dataset (ebi-a-GCST90018807) as the outcome dataset. Molecular docking, molecular dynamics simulation, and virtual knockout analysis were further used to provide structural and network-level supportive evidence. Finally, LPS-stimulated BEAS-2B cells were used as an epithelial inflammatory model to evaluate the effects of baicalein by CCK-8 assay, wound-healing assay, ELISA, and RT-qPCR. Five core genes were prioritized, namely ABCC1, CD163, CYP1B1, IKBKB, and PIK3CA. Immune infiltration and single-cell analyses suggested that macrophage-associated immune regulation may represent an important mechanistic direction. MR analysis provided supportive genetic evidence for prioritizing CD163 in COPD. Molecular simulation offered preliminary structural support for several target-compound interactions. In LPS-stimulated BEAS-2B cells, baicalein reduced inflammatory cytokine release and modulated the expression of IKBKB, PIK3CA, IL1B, IL6, and IL10, thereby providing epithelial-level support for the predicted network. Taken together, these findings suggest that baicalein may exert anti-inflammatory effects in COPD through a multi-target, immune-associated mechanism, with macrophage-related regulation and CD163 emerging as noteworthy candidate directions for further investigation. This study provides an integrative framework for target prioritization and mechanistic exploration, while the predicted macrophage-centered mechanisms still require dedicated validation in immune-cell and in vivo models.

Indexed as

FlavanonesPulmonary Disease, Chronic ObstructiveAntigens, CDAntigens, Differentiation, MyelomonocyticCD163 AntigenGene Expression ProfilingHumansMolecular Docking SimulationMultiomicsReceptors, Cell SurfaceTranscriptomeAntigens, CDAntigens, Differentiation, MyelomonocyticbaicaleinCD163 AntigenFlavanonesReceptors, Cell SurfacebaicaleinBEAS-2BCD163chronic obstructive pulmonary diseaseCOPDinflammationmacrophage-associated immune regulationmulti-omics analysistarget prioritization

Identifiers

PMID42197164
PMCPMC13209940

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.